Oncology
Page 2 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
EMA Conditional Approvals CAR-T: Insights on Relapsed B-Cell Lymphomas
This article delves into the insights and implications of EMA's conditional approvals for CAR-T therapies in the management of relapsed B-cell lymphomas.
EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval
This article delves into the EMA Conditional Approval Pathway, highlighting key insights from the oncology approval of Repotrectinib for advanced cancer treatment.
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
EC grants marketing authorization for POHERDY (pertuzumab), the first approved biosimilar to PERJETA in Europe, developed by Henlius Biotech and Organon.
PureTech Reports Positive LYT-200 Clinical Results for Myeloid Malignancies in 2025 Annual Results
PureTech announces positive clinical results for LYT-200 in myeloid malignancies, alongside Phase 3-ready deupirfenidone and advancing neuropsychiatric pipeline.
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
European Commission approves POHERDY as first pertuzumab biosimilar in Europe, offering cost-effective alternative to PERJETA for breast cancer treatment.
Novel Immunotherapies Advanced Melanoma: EMA Approval & Phase 3 Insights
Discover the groundbreaking EMA-approved immunotherapies for advanced melanoma and insights from recent Phase 3 trials shaping future treatments.
European Pediatric Investigation Plans: Accelerating Oncology Drug Development Timelines
European Pediatric Investigation Plans are crucial for expediting oncology drug development, ensuring timely access to innovative treatments for pediatric cancer patients.
Real-World Evidence Oncology Drugs: EMA vs MHRA Regulatory Approaches
This article compares the EMA and MHRA's regulatory frameworks for real-world evidence in oncology drugs, focusing on their implications for cancer treatment.
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
This article delves into the market dynamics of biosimilar oncology antibodies, focusing on their role in cancer treatment and implications for healthcare systems.
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment
Silexion Therapeutics successfully submits Phase 2/3 clinical trial application to Germany's BfArM for SIL204, targeting KRAS-driven pancreatic cancer.
EMA Conditional Approvals CAR-T: What You Need to Know on B-Cell Lymphomas
Explore the latest on EMA Conditional Approvals for CAR-T therapies targeting B-Cell Lymphomas, including treatment efficacy and patient outcomes.
EU Market Access ADCs: NICE, G-BA & HAS Assessments of Trastuzumab Deruxtecan
This article delves into the EU market access landscape for Trastuzumab Deruxtecan, focusing on assessments by NICE, G-BA, and HAS for HER2-positive cancers.